NEU 📈 Neuca S.A. - Overview
Exchange: WAR • Country: Poland • Currency: PLN • Type: Common Stock • ISIN: PLTRFRM00018
NEU: Pharmaceuticals, Dietary Supplements, Medical Devices, Dermocosmetics
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients. It provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance activities, including health insurance products. It also provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland. Web URL: https://www.neuca.pl
Additional Sources for NEU Stock
NEU Stock Overview
Market Cap in USD | 887m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Drug Retail |
IPO / Inception |
NEU Stock Ratings
Growth 5y | 58.9% |
Fundamental | 41.7% |
Dividend | 64.8% |
Rel. Strength Industry | -58.7 |
Analysts | - |
Fair Price Momentum | 919.68 PLN |
Fair Price DCF | 1275.07 PLN |
NEU Dividends
Dividend Yield 12m | 1.62% |
Yield on Cost 5y | 4.08% |
Annual Growth 5y | 11.93% |
Payout Consistency | 99.8% |
NEU Growth Ratios
Growth Correlation 3m | 6.2% |
Growth Correlation 12m | -41.1% |
Growth Correlation 5y | 66.7% |
CAGR 5y | 19.81% |
CAGR/Mean DD 5y | 1.53 |
Sharpe Ratio 12m | 0.01 |
Alpha | -9.92 |
Beta | 0.30 |
Volatility | 25.53% |
Current Volume | 1.9k |
Average Volume 20d | 1.4k |
What is the price of NEU stocks?
As of December 22, 2024, the stock is trading at PLN 877.00 with a total of 1,878 shares traded.
Over the past week, the price has changed by +0.45%, over one month by +18.73%, over three months by +7.97% and over the past year by +5.60%.
As of December 22, 2024, the stock is trading at PLN 877.00 with a total of 1,878 shares traded.
Over the past week, the price has changed by +0.45%, over one month by +18.73%, over three months by +7.97% and over the past year by +5.60%.
Is Neuca S.A. a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Neuca S.A. (WAR:NEU) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 41.69 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEU as of December 2024 is 919.68. This means that NEU is currently overvalued and has a potential downside of 4.87%.
Partly, yes. Based on ValueRay Fundamental Analyses, Neuca S.A. (WAR:NEU) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 41.69 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEU as of December 2024 is 919.68. This means that NEU is currently overvalued and has a potential downside of 4.87%.
Is NEU a buy, sell or hold?
Neuca S.A. has no consensus analysts rating.
Neuca S.A. has no consensus analysts rating.
What are the forecast for NEU stock price target?
According to ValueRays Forecast Model, NEU Neuca S.A. will be worth about 1000.5 in December 2025. The stock is currently trading at 877.00. This means that the stock has a potential upside of +14.08%.
According to ValueRays Forecast Model, NEU Neuca S.A. will be worth about 1000.5 in December 2025. The stock is currently trading at 877.00. This means that the stock has a potential upside of +14.08%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1008.8 | 15% |
Analysts Target Price | - | - |
ValueRay Target Price | 1000.5 | 14.1% |